Peter Rule, Chairman and CEO
Peter Rule has been the CEO of OptiScan Biomedical since 2006 and has served as Chairman of its Board of Directors since 2001.
Before joining OptiScan Biomedical, Mr. Rule was the Chairman and CEO of EKOS Corporation. During his tenure at EKOS he raised over $60 million in venture capital to re-direct product development efforts, resulting in the invention of the company’s peripheral vascular product line, which today generates tens of millions of dollars in revenues. During this period of time, EKOS also conducted an ischemic stroke trial (IMS II) and pioneered a new therapy for the treatment of Hemorrhagic stroke, which has been published (“SLEUTH”). EKOS was sold to BTG for ~$220 million in 2013.
Prior to EKOS, Mr. Rule was the Chairman, CEO and President of PercuSurge, Inc. Mr. Rule raised approximately $50 million for PercuSurge to develop the world’s first embolic protection system for use in interventional cardiology, documenting the product’s efficacy in numerous prospective trials, including a successful 1200 patient randomized trial (“SAFER”) that today remains the largest trial in interventional cardiology run by a venture backed company. During Mr. Rule’s leadership, PercuSurge obtained CE approval and was recommended unanimously for U.S. approval by a panel (which was subsequently granted). PercuSurge was sold to Medtronic for ~$250 million in 2001.During his tenure at PercuSurge, Mr. Rule was also one of three co-founders of Therasense, Inc., holding the position of Chairman of the Board. Under his leadership, TheraSense raised its first round of funding, recruited the CEO and VP, R & D, and redirected the company’s efforts to focus on the development of the smallest and most accurate hand-held glucose meter for the treatment of outpatient diabetes. The company was later sold to Abbott Laboratories for $1.2 billion.
Prior to PercuSurge, Mr. Rule was the President of MiniMed, Inc. He raised partner and private monies to develop the world’s smallest external insulin pump, growing revenues from zero to $75 million by the year of his departure in 1995. Also under Mr. Rule’s leadership, MiniMed refined its strategy from being an external and implantable insulin pump company, to one of an external pump company with an interstitial fluid sensing continuous glucose meter (cgms), adding the world’s first cgms to its portfolio through internal development. As President, Mr. Rule also completed a successful Initial Public Offering (IPO). The company later sold to Medtronic for $3.7 billion.
During his time at MiniMed, Mr. Rule was an industry advisor to the now famous Diabetes Control and Complications Trial (DCCT). He has over 30 years of experience in the healthcare industry and received his B.S in Economics from the University of Southern California, as well as an MBA from Harvard University.
Mr. Abramowitz is a co-founder and Managing General Partner of NGN Capital. He joined NGN Capital from The Carlyle Group in New York where he was Managing Director from 2001 to 2003, focused on U.S. buyout opportunities in the healthcare industry. Beginning July 2003, he transitioned to Senior Advisor at Carlyle in order to devote the time necessary to create a dedicated healthcare fund on behalf of Carlyle. Prior to joining Carlyle, Mr. Abramowitz worked as an Analyst at Sanford C. Bernstein & Co., where he covered the medical supply, hospital management and HMO industries for 23 years, after which he was an EGS Securities Healthcare Fund Manager.
He was voted top hospital supply and/or service analyst on the Institutional Investor Magazine “All-America Research Team” during 14 out of 20 years between 1980-2000 and made “The Team” for both healthcare services and medical supplies for nine years since 1987. Mr. Abramowitz has published several notable studies on healthcare service companies, major medical mergers and cardiovascular device innovation, among others. He has also published numerous articles in leading journals. Mr. Abramowitz earned a B.A. from Columbia University in 1972 and an MBA from Harvard Business School in 1976. Mr. Abramowitz currently sits on the Board of Directors of Valtech Cardio Ltd., Small Bone Innovations, Inc. and Akorn, Inc., as well as OptiScan. He is an observer on the boards of BeneChill, Inc., Cerapedics, Inc., and Spine View, Inc. He previously served as a Director at Sightline Technologies Ltd, acquired by Stryker; Power Medical Interventions, acquired by Covidien; and MultiPlan, acquired by BC Partners and Silver Lake; as well as on the boards of MedPointe and ConnectiCare Holdings, Inc.
Mr. Liamos has served as Insulet’s Chief Operating Officer from January 2011 – January 2014 and has served on the Board of Directors since 2005. Mr. Liamos has over 19 years of experience in the diabetes industry, recently serving as the Division Vice President of Abbott Diabetes Care. At Abbott, he was responsible for global finance and operations for the Diabetes Care division, including integrating the acquisitions of MediSense and TheraSense to its acquisition by Abbott, Mr. Liamos was with TheraSense, Inc. where he served as Chief Operating Officer and Chief Financial Officer. Previously, he served as Director of Worldwide Sourcing at LifeScan, Inc., a division of Johnson & Johnson.
Mr. Liamos is also a partner in MedVenture Associates, a venture capital firm specializing in the medical technology industry where he continues to manage certain MedVentures investments as a member of the boards of four portfolio companies. Mr. Liamos has also held various operational and financial roles at Martin Marietta and GE Aerospace for over nine years. Mr. Liamos earned a Bachelor of Science from the University of Vermont and is a graduate of the General Electric Financial Management Program.
Paul Mieyal, Ph.D.
Paul Mieyal is a Vice President and the Director of Life Sciences Investments of Wexford Capital LP. Prior to that, he was Vice President in charge of health care investments for Wechsler & Co., Inc. a private investment firm and registered broker dealer. Dr. Mieyal serves as director of Nephros, Inc., Nile Therapeutics, Inc., and several private companies. Dr. Mieyal received his Ph.D. in pharmacology from New York Medical College, a B.A. in chemistry and psychology from Case Western Reserve University, and is a Chartered Financial Analyst.
Aditya Puri is an Investment Partner at Xeraya Capital, which is responsible for life sciences investments for Khazanah Nasional Berhad, the Malaysian government’s strategic investment fund. He joined Khazanah Nasional’s Life Sciences team after moving from the greater Boston area where he was working with Healthcare and Cleantech startups affiliated with Harvard and MIT. He has more than 20 years of experience and leadership encompassing general management, private equity and venture investments, and international expansion across life science and technology industries. His prior experience includes P&L responsibility and leadership positions at Yankee Group, a global technology research and consulting company, and Corporate Development at Boston Scientific, a Fortune 500 medical device manufacturer. He serves on boards of multiple public and private life sciences companies in the U.S., and private companies outside the U.S. He received his Bachelor’s degree from the University of Southern Maine, graduating Summa Cum Laude, and his MBA from the MIT Sloan School of Management. He has also passed all parts of the U.S. Uniform CPA Examination.